In line with this molecular basis, we further provide evidence that the combination of IFN-γ and an IDO1/AhR inhibitor effectively disrupts dormant TRCs, leading to a novel tumour immunotherapeutic strategy with potential clinical applications. The gene discussed is IFNG; the disease is neoplasm.